Prometic responds to false market data report regarding insider selling

December 9, 2016 Fred Dumais

LAVAL, QUEBEC, CANADA, – December 9, 2016 – ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF), (“ProMetic” or the “Corporation”) responded today to a false market data report listing amongst others, Mr. Pierre Laurin, President and Chief Executive Officer of ProMetic, as a net seller of 8.85 million shares of ProMetic. This report is false and inaccurate. All insider activities, including those of Mr. Laurin, have been properly disclosed and filed on SEDI. Furthermore, the Corporation is unaware of any corporate developments to account for the recent decline in share price and trading activity.

While the Corporation does not generally comment publicly on market speculation or rumours, the Corporation believed it was prudent to advise investors that the report is false and that the Corporation’s CEO has not sold 8.85 million shares of the Corporation. The Corporation does not anticipate issuing any further public statement regarding any rumours or speculation in the marketplace unless required by applicable laws.

About ProMetic Life Sciences Inc.        

ProMetic Life Sciences Inc. ( is a long established biopharmaceutical company with globally recognized expertise in bioseparations, plasma-derived therapeutics and small-molecule drug development. ProMetic offers its state of the art technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own affinity technology that provides for highly efficient extraction and purification of therapeutic proteins from human plasma in order to develop best-in-class therapeutics and orphan drugs. ProMetic is also active in developing its own novel small-molecule therapeutic products targeting unmet medical needs in the field of fibrosis, anemia, neutropenia, cancer and autoimmune diseases/inflammation as well as certain nephropathies. Headquartered in Laval (Canada), ProMetic has R&D facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK and commercial activities in the U.S., Canada, Europe, Russia, Asia and Australia.

Forward Looking Statements

This press release contains forward-looking statements about ProMetic’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic’s ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in ProMetic’s Annual Information Form for the year ended December 31, 2015, under the heading “Risk and Uncertainties related to ProMetic’s business”. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations. All amounts are in Canadian dollars unless indicated otherwise.

About the Author

Fred Dumais

Fred is responsible for leading Prometic’s investor relations team and is accountable for all global investor relations activity, PR and event management. He joined the company in 2001, and brings nearly twenty years of experience in investor and financial communications, as well as a deep experience of the pharmaceutical industry. He has extensive knowledge of the global financial markets in the US, Europe and his native country of Canada. Fred is a graduate from Concordia University where he gained a BA in Business Communications. He also brings to the role a background in law with a LLB from the University of Québec.

Previous Article
Prometic comments on unusual trading activity
Prometic comments on unusual trading activity

Responded today at the request of the Investment Industry Regulatory Organization of Canada (“IIROC”) on be...

Next Article
Prometic presents PBI-4050’s positive effect on diabetic patients’ kidneys at the American Society of Nephrology annual meeting
Prometic presents PBI-4050’s positive effect on diabetic patients’ kidneys at the American Society of Nephrology annual meeting

“We have several presentations at this year’s ASN meeting providing further substantial evidence of PBI-405...